| Ytd | -37.95% | |
| 1y | 13.41% |
| Open | 3.10 | Prev Close | 3.02 | Low | 2.96 | High | 3.10 | Mkt Cap | 19.08M |
| Vol | 9.37K | Avg Vol | 27.04K | EPS | -1.47 | P/E | -2.05 | Forward P/E | -0.72 |
| Beta | 0.26 | Short Ratio | 0.75 | Inst. Own | 9.90% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-18 | 50-d Avg | 3.57 | 200-d Avg | 4.46 | 1yr Est | 11.56 |
EVAX News
Three-year data from phase 2 trial will provide additional insights into potentially enhanced treatm
COPENHAGEN, Denmark, July 17, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBi
The new data demonstrates the potential to improve control of acute infection, latency, and viral re
COPENHAGEN, Denmark, July 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBi
New preclinical data will guide antigen selection for a broadly protective cytomegalovirus vaccine c
COPENHAGEN, Denmark, July 1, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio
COPENHAGEN, Denmark, June 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBi
COPENHAGEN, Denmark, June 11, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBi
COPENHAGEN, Denmark, May 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio
Evaxion A/S (EVAX) Q1 2026 Earnings Call Transcript
COPENHAGEN, Denmark, May 7, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio
COPENHAGEN, Denmark, May 4, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio
COPENHAGEN, Denmark, April 27, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechB
COPENHAGEN, Denmark, April 17, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechB
COPENHAGEN, Denmark, April 16, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechB
Shares of Evaxion A/S - Sponsored ADR (NASDAQ: EVAX - Get Free Report) have received a consensus rat
COPENHAGEN, Denmark, March 30, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechB
COPENHAGEN, Denmark, March 19, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechB
Evaxion A/S - Sponsored ADR (NASDAQ: EVAX - Get Free Report) has received a consensus recommendation
Evaxion A/S (EVAX) Q4 2025 Earnings Call Transcript
Evaxion A/S - Sponsored ADR (NASDAQ: EVAX - Get Free Report) was the recipient of a significant grow
COPENHAGEN, Denmark, March 5, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBi
COPENHAGEN, Denmark, March 5, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBi
Gainers Armstrong Flooring, Inc. (NYSE: AFI) shares jumped 237% to settle at $0.49 on Wednesday a
Companies Reporting Before The Bell • Great Elm Capital (NASDAQ:GECC) is expected to report earn
Companies Reporting Before The Bell • CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report